Life Sciences M&A Report 2023

2023 showed slow signs of recovery for global life science M&A activity compared to the previous year, both in terms of the number and value of deals. While the macroeconomic challenges and uncertainty in the geopolitical landscape that fueled the 2022 slowdown carried over into 2023, there are indications that dealmakers were approaching 2023 with … Continue reading Life Sciences M&A Report 2023

Read more

The Current State of M&A Activity in the Life Sciences Industry

The life sciences industry is no stranger to mergers and acquisitions (M&As), helping to expand product portfolios, access new markets and pursue new innovations, amongst a myriad of other reasons. In this article, we will look at the current state of M&A activity based on data from the Biotechgate database, with insights on where the … Continue reading The Current State of M&A Activity in the Life Sciences Industry

Read more

Life Sciences M&A Report: Half-Year 2023

In the first half of 2023, the slowdown in terms of global life sciences M&A deal-making experienced in the second half of 2022 has continued to show its effects. Anticipated as a year of recovery, 2023 was expected to leverage M&A as a means to adapt to rapidly changing market conditions. However, while it remains … Continue reading Life Sciences M&A Report: Half-Year 2023

Read more

Introducing M&A deals to Biotechgate

Biotechgate is continuously working on enhancements and new tools to boost the experience for our users. Currently, Biotechgate is developing a new release, which is planned for early 2024: Among the various new features that subscribers can look forward to, one in particular worth highlighting revolves around M&A deals and is unique on the market … Continue reading Introducing M&A deals to Biotechgate

Read more

Life Sciences M&A Report

In line with the broader negative trend in overall M&A investment worldwide, the global M&A activity in the life sciences industry experienced a slowdown in 2022: M&A activity declined significantly in both the number and value of deals compared to the previous year. However, there is hope that 2023 will be a more active year … Continue reading Life Sciences M&A Report

Read more

The 8 Largest Biopharma M&A Deals of 2022 (Jan-Sep)

Despite 2022 being a relatively quiet year for M&A activity within the biopharma space, especially when compared to 2021, a number of prominent deals have taken place. Find out the 8 largest M&A deals of the year so far in order of the total amount. 8. Zogenix Acquired by: UCB Amount: USD 1.9bn After Zogenix’s … Continue reading The 8 Largest Biopharma M&A Deals of 2022 (Jan-Sep)

Read more